Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.

Conclusions: The efficacy and safety of BOC- and TVR-based triple therapy in this large, "real-world" cohort were largely comparable to that reported in pivotal clinical trials, although SVR rates were lower overall. Recommended futility or treatment extension rules were violated in a substantial proportion of patients with potential implications for response, adverse events and costs.
PMID: 26167694 [PubMed - as supplied by publisher]

Source: Zeitschrift fur Gastroenterologie - July 1, 2015 Category: Gastroenterology Authors: Mauss S, Böker K, Buggisch P, Christensen S, Hofmann WP, Schott E, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D Tags: Z Gastroenterol Source Type: research